Literature DB >> 35530270

Construction of AP003469.4-miRNAs-mRNAs ceRNA network to reveal potential biomarkers for hepatocellular carcinoma.

Tengyang Fan1, Guojun Jiang2, Rongshu Shi2, Ronghua Yu3, Xue Xiao1, Di Ke1,2.   

Abstract

Studies have reported that the competing endogenous RNA (ceRNA) networks are related to disease progression and prognosis in patients with hepatocellular carcinoma (HCC). The roles and mechanisms of long-chain non-coding RNA AP003469.4 in HCC have remained unclear. Here, we explored the roles of AP003469.4 in HCC progression using bioinformatics, CCK-8, Transwell assay, etc. AP003469.4 targets miRNAs and these target genes were predicted by the LncBase Predicted v.2, miRDB, miRTarBase, and TargetScan databases. Then, AP003469.4-associated ceRNA network was constructed. Biological functions and mechanisms of differentially expressed genes in the ceRNA network were explored using GO and KEGG. Survival analysis and Cox regression analysis were used to screen prognostic genes and construct a prognostic risk model. The results revealed that AP003469.4, with the area under the curve of 0.9048, was highly expressed in HCC tissues. Increased expression of AP003469.4 was an independent risk factor for the dismal prognosis of HCC patients and was associated with the short overall and disease-free survival. Downregulation of AP003469.4 expression inhibited cell proliferation, cycle transition, invasion, and migration, and promoted cell apoptosis. There were 489 differentially expressed target genes in the ceRNA network, which were involved in several pathways, such as the MAPK signaling pathway, cell cycle, and p53 signaling pathway. The risk model was based on the DTYMK, ZFC3H1, CBX2, PKM, TTC26, ATG10, TAGLN2, CD3EAP, SHISA9, SLC1A5, KPNA2, SCML2, E2F7, and SMARCD1, which were the independent risk factors for poor prognosis of HCC patients. In general, interference with AP003469.4 expression might delay the progression of HCC. AP003469.4 related network could help to identify the hub target molecules in HCC progression, which might be candidate biomarkers for evaluating the prognosis of HCC patients. AJCR
Copyright © 2022.

Entities:  

Keywords:  AP003469.4; competing endogenous RNAs; disease-free survival; hepatocellular carcinoma; overall survival

Year:  2022        PMID: 35530270      PMCID: PMC9077056     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  36 in total

1.  Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types.

Authors:  Xinggang Guo; Zhiheng Wang; Jianing Zhang; Qingguo Xu; Guojun Hou; Yuan Yang; Chuanpeng Dong; Gang Liu; Chenhua Liang; Lei Liu; Weiping Zhou; Hui Liu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2019-03-01       Impact factor: 3.848

2.  ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression.

Authors:  Peng Li; Jie He; Zhi Yang; Shengfang Ge; He Zhang; Qing Zhong; Xianqun Fan
Journal:  Autophagy       Date:  2019-09-03       Impact factor: 16.016

3.  LncRNA RUSC1-AS1 promotes the proliferation of hepatocellular carcinoma cells through modulating NOTCH signaling.

Authors:  Y A Chen; L Cheng; Y Zhang; L Peng; H G Yang
Journal:  Neoplasma       Date:  2020-07-23       Impact factor: 2.575

4.  Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10+ diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  David Azoulay; Hector I Cohen; Eugene Dementiev; Elizabeth Eshel; Luiza Akria; Ety Shaoul; Netanel Horowitz
Journal:  Cytometry B Clin Cytom       Date:  2019-12-09       Impact factor: 3.058

5.  Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway.

Authors:  Yongjie Zhou; Qing Xu; Lv Tao; Yuwei Chen; Yuke Shu; Zhenru Wu; Changli Lu; Yujun Shi; Hong Bu
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

6.  MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.

Authors:  P Zhang; W M Tang; H Zhang; Y Q Li; Y Peng; J Wang; G N Liu; X T Huang; J J Zhao; G Li; A M Li; Y Bai; Y Chen; Y X Ren; G X Li; Y D Wang; S D Liu; J D Wang
Journal:  Br J Cancer       Date:  2017-06-20       Impact factor: 7.640

7.  MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma.

Authors:  Donghui Zhang; Enqin Liu; Jian Kang; Xin Yang; Hong Liu
Journal:  Oncotarget       Date:  2017-10-10

8.  E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.

Authors:  Yanjie Wang; Ruixun Lu; Xiaofeng Jiang; Xinhui Chen; Nan Meng; Min Chen; Shan Xie; Guang-Rong Yan
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

9.  Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma.

Authors:  Wen-Jie Wang; Han Wang; Ting-Yan Hua; Wei Song; Jie Zhu; Jing-Jing Wang; Yue-Qing Huang; Zhi-Liang Ding
Journal:  Front Genet       Date:  2020-02-25       Impact factor: 4.599

10.  MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7.

Authors:  Yichao Zhao; Chaoqian Zhu; Qing Chang; Peng Peng; Jie Yang; Chunmei Liu; Yang Liu; Xiaonan Chen; Yuanguang Liu; Ran Cheng; Yijie Wu; Xiaotang Wu; Liang Hu; Jun Yin
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

View more
  1 in total

1.  The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.

Authors:  Dan Li; Kai Li; Wei Zhang; Kong-Wu Yang; De-An Mu; Guo-Jun Jiang; Rong-Shu Shi; Di Ke
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.